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Abstract 
 The objective of this study was to evaluate the number of medicines 
and active ingredients for pediatric population that are authorized and 
marketed in Albania. For this purpose were selected two group’s medicines: 
H2 antihistaminics and Proton Pump Inhibitors.  The availability of pediatric 
medicines and active ingredients was studied with the help of the database of 
the Albanian National Agency for Medicine and Medical Devices and 
SmPCs. Selected active ingredients were categorized based on their route of 
administration, type of pharmaceutical form, dosage, therapeutic indication, 
dose capability and suitability of the pharmaceutical form for use in children.  
From evaluation of SmPCs of selected products for the authorized age - 
group were found that 58 products are also authorized for use in children. 
Two of the active ingredients are authorized only for use in adults. The 
analyze of aspect if the recommended dose prescribed based on the 
classification of pediatric age stated give these data’s: 35 products are 
authorized for use children and adolescents from 3–18 years and 23 products 
are authorized for use in children more than 1 year old.  This study shows a 
lack of availability of pediatric medicines for selected products and shows 
that pediatric medicines may not be age-appropriate; even they are 
authorized for such use. It was shown that few medicinal products are 
specifically studied in children. Therefore, are needed more efforts to 
increase the number of drugs authorized for the pediatric groups. Even more, 
it is required by pharmaceutical companies to supply data on the effects of 
new drugs in children. 
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Introduction  
 The lack of appropriate pediatric formulations is a worldwide 
problem (Giacoia et al. 2007). Pharmaceutical companies developed 
dedicated preparations for pediatric patients mainly if the products are likely 
to be marketable and will generate profit for the manufacturer (Pawaret al. 
2002). Physicians often have prescribed unauthorized medicinal products 
due to lack of suitable and authorized medicine for children, in order to 
provide medical assistance to them (Chui J et al. 2004, Chui J et al. 2005, 
Cuzzolin L et al. 2006, Kairuz TE et al. 2006).This attitude seems to lead to 
an increased rate of adverse drug reactions and medical errors (Young L et 
al. 2009, EU Regulation no 19012006, Auby 2008). 
 Due to different strategies of Pediatric Regulation in the EU, 
approved on January 2007, the pharmaceutical industry is obliged to plan 
clinical trials in children at an early stage of the development of medicines 
containing a new active substance. The same requirement applies to the 
development of a new indication for existing medicinal drug products 
(Breitkreutz 2008, Ceci A et al. 2002). The design of currently authorized 
pediatric medicines is not always optimal (Cohen R et al. 2009). Sometimes 
tablets have been authorized for children below the age of 6 years, even 
though they may be not able to swallow tablets (Cohen R et al. 2009). 
Therefore, it is very important to study if authorized medicines are really 
adequate for use in children.  
 The first objective of this study was to evaluate the number of 
medicines and active ingredients for pediatric population that are authorized 
and marketed in Albania, for selected groups. Also, as an additional 
objective was to evaluate the age-appropriateness of the selected medicines 
based on their suitability of authorized dose and pharmaceutical form for use 
in children. 
 
Methods 
 With the help of the database of medicines of the Albanian National 
Agency for Medicine, until 10 April 2015, was identifies authorized 
medicines for below stated active ingredients. In total was studied 84 
medicinal products from selected active ingredients. For this study was 
selected and evaluated below mentions pharmaceutical groups: H2 
Antihistaminics: Ranitidine; Proton Pump Inhibitors: Omeprazole, 
Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole. 
 Database of medicines in Albanian is updated on a monthly level and 
contains all medicinal products authorized in Albania from National Agency 
for Medicine and Medical Devices and Ministry of Health. Authorized 
medical products refer to a single dosage or pharmaceutical form. For each 
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product were analyzed major characteristics as the route of administration, 
e.g. oral, intramuscular, approved dosage and pharmaceutical form. 
 This database doesn’t allow extraction of marketed products and 
active ingredients classified based on age-appropriateness. For this reason 
were evaluated Summary of Product Characteristics (SmPC). Based on the 
Albanian regulation of approving products texts at the same time performed 
by the referent country of Marketing Authorization, the information of 
authorized SmPCs was checked in databases of Medicines Compendium, 
Irish Pharmaceutical Healthcare Association, Croatian Agency for Medicinal 
Products and Slovenian Agency of Medicinal Products. From published 
SmPCs were analyzed sections: pharmaceutical form, therapeutic 
indications, posology, and route of administration.  
 A special focus was dedicated to age-appropriateness of selected 
products. First investigated aspect was if recommended dose is prescribed to 
children based on the classification of pediatric age stated in Tablets 1 (ICH 
Topic E 11).  
Table 1. Classification of pediatric population 
Groups Age 
Preterm newborn infants  
Term newborn infants 0 – 27 days 
Infants and toddlers 28 days – 23 months 
Children 2 – 11 years 
Adolescents 12 to 16-18 years (dependent on region) 
 
 Second investigated aspect was if approved pharmaceutical form, for 
selected products in this study, were suitable for use in children. If 
pharmaceutical form were considered as not suitable e.g., tablets 150 mg for 
children 3 years old), were verified the presence of an alternative form e.g. 
liquid pharmaceutical forms. For solid forms (such as tablets and capsules) 
were evaluated the presence of the score line and the possibility of opening 
or not contains capsules. 
 Based on all prescribed methodology use for this study were 
collected these data: authorized indications; authorized age-group; 
pharmaceutical form; authorized dosage; the presence of score line; 
information on the possibility for opening capsules contains. 
 
Results and Discussions 
 The availability of selected medicines and active ingredients are 
described in Table 2.Were found 20 authorized products containing 
Ranitidine; 23 authorized products containing Omeprazole; 11 authorized 
products containing Esomeprazole; 4 authorized products containing 
Lansoprazole; 25 authorized products containing Pantoprazole; and 1 
authorized products gastro-resistant tablets 20 mg containing Rabeprazole. 
European Scientific Journal March 2016 edition vol.12, No.9  ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
215 
Table 2: Availability of selected medicines for the study 
Active 
ingredient 
Therapeutic 
class 
Authorized 
indication 
Authorized age-
group 
Authorized 
form and 
strength 
Number 
of  
products 
Ranitidine 
H2 
Antihistaminics 
Reflux 
oesophagitis, 
benign gastric 
and duodenal 
ulceration, 
prophylaxis of 
duodenal 
ulceration 
Adults, 
Children and 
adolescents from 3 – 
18 years 
Film-coated 
tablets 150 mg; 
Solution for 
injection 50 
mg/ml 20 
Omeprazole 
 
Proton Pump 
Inhibitors 
GER, duodenal 
and gastric 
ulcers, 
Zollinger-
Ellison 
syndrome, 
Helicobacter 
eradication 
therapy 
Adults, 
Capsules > 1 year, 
Powder for solution 
for injection > 1 year 
Gastro-resistant 
capsules 20 mg; 
Powder for 
solution for 
injection 40 
mg/vial 23 
Esomeprazole 
Proton Pump 
Inhibitors 
Duodenal and 
gastric ulcers, 
GER 
Adults, 
Adolescents >12years 
Gastro-resistant 
tablets and 
capsules 20 mg 
and 40 mg; 
Powder for 
solution for 
injection 40 
mg/vial 11 
Lansoprazole 
Proton Pump 
Inhibitors 
Duodenal and 
gastric ulcers, 
GER, 
helicobacter 
pylori 
eradication, 
prophylaxis in 
reflux 
oesophagitis 
Adults, 
Adolescents >12years 
Capsules 15 mg 
and 30 mg 4 
Pantoprazole 
Proton Pump 
Inhibitors 
GER, duodenal 
and gastric 
ulcers, Zollinger 
Ellison-
syndrome, 
Helicobacter 
eradication 
therapy Adults 
Gastro-resistant 
tablets 20 mg 
and 40 mg; 
Powder for 
solution for 
injection 40 
mg/vial 25 
Rabeprazole 
Proton Pump 
Inhibitors 
Duodenal and 
gastric ulcers, 
GER, 
helicobacter 
pylori 
eradication Adults 
Gastro-resistant 
tablets 20 mg 1 
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 From evaluation of the SmPCs of selected products for the authorized 
age - group were found that 58 products (69 %) are also authorized for use in 
children. Two of the active ingredients Pantoprazole and Rabeprazole are 
authorized only for use in adults. The analyze of aspect if recommended dose 
is prescribed to children based on classification of pediatric age stated give 
these data’s: 35 products (60.34 %) are authorized for use children and 
adolescents from 3 – 18 years and 23 products (39.66 %) are authorized for 
use in children more than 1 year old (figure 1). 
 
Figure 1: Authorized age-groups of products based on dose prescribed for children 
 
 Evaluation of SmPCs for age-appropriateness of these products on 
the suitability of pharmaceutical forms showed that all products are 
authorized as solid oral forms and as a solution for injections. All approved 
pharmaceutical forms are as follows: 14.3 % (n = 12) film coated tablets, 
20.2 % (n = 17) solution for injection, 28.6 % (n = 24) gastro-resistant 
capsules and 36.9 % (n = 31) gastro-resistant tablets (figure 2). For any 
active ingredient wasn’t found authorized liquid formulations, which are 
more appropriate for use in children. 
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Figure 2: Authorized pharmaceutical forms for studied products 
 
 Results of investigation of solid approved form (tablets and capsules) 
for presence of score line in order to archives smaller dosages are as 
following: from 12 authorized products Ranitidine 150 mg film-coated 
tablets, 75 % (n = 9) of authorized products they were without score line, 
16.7 % (n = 2) were with score line on one side of tablet and 8.3 % (n = 1) 
was with score line on both sides of tablets (figure 3).  
 
Figure 3: Presence of score line in Ranitidine 150 mg film coated tablets 
 
 This shows that only a few products in solid forms are suitable for 
archives smaller dosages than those for adults, in order to have an exact 
dosage needed for children treatment. 
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 As it is known that children below the age of 6 years may be not able 
to swallow tablets (Cohen R et al. 2009), we evaluate the possibility of 
opening capsules and use it contains orally. Information studied from SmPCs 
of products available in capsules shows that only for Omeprazole authorized 
products is stated that patients can open the capsule and swallow the contents 
with half a glass of water or after mixing the contents in a slightly acidic 
fluid and that the dispersion should be taken immediately (or within 30 
minutes). 
 
Conclusion 
 This study shows a lack of availability of dosage forms for selected 
products and shows that pediatric medicines may not be age-appropriate; 
even they are authorized for such use. It was shown that few medicinal 
products are specifically studied in children. Also, it is shown that medicines 
authorized for children may differ with respect to their ability to provide the 
recommended dose and suitability of pharmaceutical form. Therefore, are 
needed more efforts to increase the number of drugs authorized for the 
pediatric groups. Even more, it is required by pharmaceutical companies to 
supply data on the effects of new drugs in children. The dose capability was 
considered important criteria. A medicine is either dose capable or it is not. 
However, the suitability of pharmaceutical forms is not as absolute. 
According to EU reflection paper tablets and capsules are only suitable for 
the age of 6 years. However, recent studies have shown that small tablets can 
be swallowed by young children (Thomson SA et al. 2009, Sturkenboom 
MC et al. 2008). Also, some capsules can be opened and can be ready for use 
if contains is mixed with water or liquids. 
 Physicians and pharmacists should consider that by using formulation 
not appropriate for children may cause administration errors, lack of 
therapeutic income and unexpected side effects. In order to reduce the risk of 
any of below problems, they are encouraged to search for marketed products 
the most appropriate medicine for treating groups of the pediatric population. 
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